Consent given pursuant to Sections 14 and 14A to the importation and supply of therapeutic goods specified - Apotex Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the importation, supply, and other dealings with therapeutic goods in Australia, addressing the need for a comprehensive legal framework to ensure the safety, quality, and efficacy of such goods. The Act was developed by the Parliament of Australia to safeguard public health by controlling the therapeutic goods market, ensuring that only products that meet specified standards are available for use. The policy objective underpinning the Act is to protect and promote public health by regulating therapeutic goods, thereby reducing the risk of harm to consumers. In specific instances, such as the case highlighted in the gazette notice, the Act allows for certain exceptions to its stringent regulatory requirements under controlled conditions to facilitate access to necessary treatments while maintaining the overall safety and quality standards.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods in Australia, encompassing a broad range of products including medicines, medical devices, blood and blood components, tissues, and in vitro diagnostic goods. The Act applies to all entities involved in the supply, manufacture, evaluation, advertising, and importation of these goods within Australia. The scope of the Act extends across the Commonwealth, ensuring a unified regulatory framework that applies nationally, though it is complemented by state and territory legislation in certain instances. The Act includes provisions for exemptions and exclusions, such as over-the-counter medicines and certain low-risk medical devices, which are subject to specific thresholds and conditions. Under the Act, the application and scope can be extended or restricted through subordinate instruments, such as regulations and orders, which provide detailed rules and standards that must be met by entities and products. The Therapeutic Goods Order No. 69, for instance, specifies the general requirements for labels for medicines, including the necessity of batch numbers and expiry dates, although exceptions can be granted by the Secretary's delegate, as demonstrated in the case of Apotex Pty Ltd's consent for the importation and supply of Betahistine dihydrochloride.

Key Provisions

The Therapeutic Goods Act 1989, specifically under sections 14 and 14A, outlines the process by which consent can be given for the importation and supply of therapeutic goods that do not fully comply with certain regulatory requirements. In this instance, section 14 allows the delegate of the Secretary of the Department of Health to provide consent for the importation and supply of Betahistine dihydrochloride (APO-BETAHISTINE) 16 mg uncoated tablet blister packs (section 14(1)). This consent is given on the condition that the product does not conform with certain labelling requirements as specified in Therapeutic Goods Order No. 69. Specifically, the product in question lacks the batch number and expiry date prefixes on both the blister foil and carton labels (section 14A(2)). This consent is subject to certain conditions to ensure that the therapeutic goods can still be safely and effectively used by consumers. Under section 15(1) of the Act, the delegate has stipulated that a Dear Customer letter must be supplied to pharmacists. This letter, which is identical to the one provided to the Therapeutic Goods Administration on November 28, 2014, must inform pharmacists where the batch number and expiry date can be found on the product (section 15(1)(a)). This requirement ensures that despite the non-compliance with labelling standards, pharmacists and consumers are still able to access critical information regarding the product's batch and expiry dates. The obligations imposed by this consent are clear and designed to mitigate any potential risks associated with the non-compliant labelling. Apotex Pty Ltd must ensure that the Dear Customer letter is distributed to all relevant pharmacists, providing them with the necessary information to manage the supply and use of the product effectively. This obligation ensures that the therapeutic benefit of the product is not compromised, and that consumers can still use the product safely. Failure to comply with the conditions of this consent may result in enforcement actions under the Act. While specific offences and penalties are not detailed in the text, the Therapeutic Goods Act generally provides for both civil and criminal penalties for breaches of its provisions. Civil penalties can include fines up to a significant amount, and criminal penalties can include imprisonment, reflecting the serious nature of ensuring the safety and efficacy of therapeutic goods in Australia. The exact penalties would depend on the specific nature and severity of the breach, but they serve as a deterrent to non-compliance.